Astrea Bioseparations Acquires Delta Precision
Astrea Bioseparations has acquired Delta Precision, a manufacturer of chromatography columns for biomanufacturing.
Astra Bioseparations (Astrea Bio), a provider of bioseparation and purification technologies, announced on Jan. 9, 2023 that it has acquired Delta Precision, a manufacturer of advanced chromatography columns for the biotechnology and pharmaceutical industries.
The acquisition will allow Astrea Bio to expand its product offerings to include a full range of high-performance chromatography columns for biomanufacturing. This will add to its existing portfolio of bioprocessing resins, reusable columns, and prepacked single-use columns. Delta Precision’s products are used in a variety of applications, including protein purification, vaccine production, and drug development.
“We are delighted to welcome the Delta team into the fold. The acquisition of Delta is another step forward in Astrea Bio’s rapid expansion to support the biopharmaceutical manufacturing field,” said Terry Pizzie, CEO of Astrea Bio. “This is a highly strategic move for us, allowing us to offer a full range of industry-leading purification and separation tools.”
“We look forward to joining the Astrea Bio family, further cementing the long-standing relationship between the two companies,” added Geoff Parnell, o-founder and managing director at Delta Precision. “We are confident that our expertise in column manufacturing will complement and accelerate the Astrea Bio business and customer reach.”
Source: Astrea Bio
Drug Shortages and Complying with FDA’s 21 CFR 211.110 Guidance
April 2nd 2025Susan J. Schniepp, distinguished fellow at Regulatory Compliance Associates, and Rona LeBlanc-Rivera, PhD, principal consultant, Regulatory Affairs at Regulatory Compliance Associates, answer some questions about FDA’s January 2025 21 CFR 211.110 guidance document.
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
